| DiGiovanna, Michael |
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation |
|
|
| Completed | 4 | 339 | US | Dronedarone, Multaq | American Heart Association, Duke Clinical Research Institute, Sanofi | Atrial Fibrillation | 01/24 | 06/24 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects |
|
|
| Recruiting | 3 | 750 | Europe, US | Placebo, GLSI-100 | Greenwich LifeSciences, Inc. | Breast Cancer | 12/26 | 12/26 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Martin |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
| Recruiting | 2 | 200 | Europe | RNU, Radical nephro-ureterectomy, Gemcitabine/Cisplatin, Gemcitabine plus Cisplatin, M-VAC Protocol, DD MVAC | The European Uro-Oncology Group, Centre for Human Drug Research, Netherlands | Upper Tract Urothelial Carcinoma | 12/24 | 12/25 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
NCT05814016: A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery |
|
|
| Terminated | 2 | 41 | US | Danavorexton, TAK-925, Placebo | Takeda | Sleep Apnea | 09/24 | 09/24 | | |
NCT05740982: A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox |
|
|
| Active, not recruiting | 2 | 450 | US | JYNNEOS | National Institute of Allergy and Infectious Diseases (NIAID) | Monkeypox | 08/24 | 06/25 | | |
| Active, not recruiting | N/A | 20 | Europe | Formula diet | West German Center of Diabetes and Health | Steatohepatitis, Nonalcoholic | 12/24 | 03/25 | | |
FARA1000, NCT05501873: Real World Data Collection in Subjects Treated with the FARAPULSE Pulsed Field Ablation System |
|
|
| Active, not recruiting | N/A | 1173 | Europe, RoW | FARAPULSE Pulsed Field Ablation system | Boston Scientific Corporation | Atrial Fibrillation | 08/27 | 08/27 | | |
| Seminario, Teodoro |
NCT06742281: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults |
|
|
| Recruiting | 2 | 10016 | US | CVXGA (CVXGA50), COMIRNATY® | CyanVac LLC, Biomedical Advanced Research and Development Authority | COVID-19 | 06/26 | 06/27 | | |
| Broom, Colin |
PUL-042-207, NCT06665100: PUL-042 Treatment in Patients with Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) |
|
|
| Not yet recruiting | 2 | 100 | US | PUL-042, Placebo | Pulmotect, Inc., Cancer Prevention Research Institute of Texas | Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | 01/26 | 01/26 | | |
| Naeem, Mustafa |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
| Hasan, Sarah |
| Completed | 4 | 698 | Europe, Canada, US | Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing | Pfizer, Biohaven Pharmaceuticals Holding Company Limited, Pfizer Inc. | Migraine | 10/24 | 12/24 | | |
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles |
|
|
| Completed | 3 | 1319 | Canada, US | MR-100A-01, Transdermal contraceptive delivery system | Mylan Technologies Inc., Mylan Inc. | Contraception | 01/25 | 01/25 | | |
